CHI3L1: Multifunctional Secreted Glycoprotein for Liver‑Fibrosis‑Oriented Basic‑Research Investigations

Molecular Features of CHI3L1: Structural Basis for Loss of Chitinase Catalytic Activity

CHI3L1, alternatively named YKL‑40, represents a secreted monomeric glycoprotein encoded by the human CHI3L1 gene. This polypeptide contains 383 amino‑acid residues with an approximate molecular weight of 40 kDa and belongs to glycoside hydrolase family 18.

It folds into a canonical (β/α)8 TIM‑barrel domain plus an insertion domain built from six antiparallel β‑strands. The protein retains chitin and chito‑oligosaccharide binding capacity via nine distinct GlcNAc‑binding sub‑sites within its interaction interface.

Sequence alteration inside the conserved catalytic motif replaces DXXDXDXE with DGLDLAWL, which abolishes intrinsic chitin‑hydrolysing enzymatic capacity. This key sequence change categorizes CHI3L1 as a chitinase‑like protein without functional catalytic activity.

Within hepatic‑tissue model systems, CHI3L1 transcript and protein products are mainly secreted by hepatic macrophages, neutrophils, fibroblast‑like cells and activated hepatic stellate cell populations. Its expression magnitude remains comparatively low across most other non‑hepatic tissue specimens under baseline physiological conditions.

Biological Roles of CHI3L1 in Inflammation, Tissue Remodelling and Fibrogenesis

CHI3L1 participates in multiple pathological molecular programmes, and its regulatory mechanisms remain under ongoing basic‑research exploration. Elevated CHI3L1 abundance has been documented in experimental models for asthma, sepsis, diabetes, rheumatoid arthritis and coronary‑artery‑disease‑related phenotypes.

In liver‑biology laboratory assays, CHI3L1 expression rises markedly under fibrotic‑disease experimental conditions. It drives hepatic stellate‑cell activation, modulates inflammatory signalling outputs and facilitates extracellular‑matrix remodelling events within liver‑tissue microenvironments.

CHI3L1 can trigger NF‑κB‑centred signalling cascades to adjust transcription levels of multiple pro‑inflammatory mediator genes in cultured immune and stromal cell populations. Pre‑clinical perturbation experiments deploy CHI3L1‑targeting monoclonal antibodies to interfere with its molecular functions.

In mouse metabolic‑associated steatohepatitis model systems, antibody‑mediated CHI3L1 neutralization alleviates measurable fibrotic phenotypic readouts. These experimental observations suggest CHI3L1 serves not merely as a readout marker but also as an active functional mediator in hepatic fibrogenesis pathways.

Research‑Oriented Biomarker Exploration of CHI3L1 for Liver‑Fibrosis Model Evaluation

Liver fibrosis represents shared pathological outcome originating from diverse chronic hepatic‑injury experimental model systems. Progressive fibrosis can advance toward cirrhosis and hepatocellular‑carcinoma‑associated phenotypes in long‑term animal‑model observations.

Early‑phase fibrotic alterations possess partial reversibility in biological models, making reliable staging‑marker identification a meaningful basic‑research objective. Liver biopsy acts as reference standard yet suffers from invasive sampling constraints and sampling‑bias‑related limitations for large‑scale sample‑cohort analysis.

Conventional serum indices including APRI and FIB‑4 alongside elastography readouts also exhibit measurable performance limitations for precise stratification of early‑stage fibrotic sample cohorts. Multiple pre‑clinical dataset analyses demonstrate circulating CHI3L1 concentrations increase gradually along with advancing liver‑fibrosis severity grades.

In hepatitis‑B‑related experimental sample cohorts, CHI3L1 achieves an AUROC value of 0.97 when distinguishing significant fibrosis ranging from F2 to F4 stages. Such performance compares favourably against APRI, FIB‑4 and liver‑stiffness‑derived assessment parameters in comparative analytical workflows.

For Chinese hepatitis‑B‑related sample sets, CHI3L1 shows improved analytical performance relative to hyaluronic acid and N‑terminal procollagen‑III peptide markers. Multicohort datasets indicate CHI3L1 maintains discriminatory capacity even among samples with normal ALT readouts. Machine‑learning‑based model‑building assigns up to 62.2 % feature‑contribution weight to CHI3L1 within combined‑marker prediction pipelines.

Technical Requirements for CHI3L1‑Focused Immunoassay‑Development Research

High‑specificity monoclonal antibody reagents constitute essential experimental foundations for CHI3L1‑oriented biomarker‑mechanism investigations. Recombinant monoclonal antibodies reduce batch‑to‑batch variation compared with traditional polyclonal antibody preparations for immuno‑assay construction projects.

Validated CHI3L1 antibody products support multiple common laboratory detection platforms including sandwich‑format ELISA, Western blot and chemiluminescent immunoassay workflows. Researchers need to complete comprehensive specificity verification to exclude cross‑reactivity signals from homologous chitinase‑family protein members.

Appropriate matrix‑matched positive and negative biological sample controls should be incorporated during assay development and performance‑validation cycles. Well‑characterized antibody pairs enable building quantitative detection workflows for measuring secreted CHI3L1 abundance within cell‑culture supernatant and serum‑derived sample material.

These immuno‑assay tool sets support basic‑research projects exploring fibrogenesis mechanisms, biomarker‑panel construction and compound‑intervention phenotypic evaluation in liver‑disease‑model experimental systems.

Research‑Grade Reagent Portfolio for CHI3L1‑YKL‑40‑Related Basic‑Research

ANT BIO PTE. LTD. provides validated CHI3L1 recombinant rabbit monoclonal antibody reagents dedicated exclusively to non‑clinical laboratory‑research projects. These antibody resources support protein quantification, immunoblot analysis and immunoassay development for hepatic‑fibrosis‑mechanism and biomarker‑screening investigative workflows.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.